reference/2416474

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/2416474

Outgoing Links

Predicate	Object
contentType	Comparative Study\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	1059
issn	1474-4422
issueIdentifier	11
pageRange	1053-1059
publicationName	The Lancet. Neurology
startingPage	1053
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_0aaf6f65db41a4707c8f1c7248ee718a http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_12dc3632b59fad5db2ab7c79fa76eb9e
bibliographicCitation	Kirschner J, Schessl J, Schara U, Reitter B, Stettner GM, Hobbiebrunken E, Wilichowski E, Bernert G, Weiss S, Stehling F, Wiegand G, Müller-Felber W, Thiele S, Grieben U, von der Hagen M, Lütschg J, Schmoor C, Ihorst G, Korinthenberg R. Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial. Lancet Neurol. 2010 Nov;9(11):1053–9. doi: 10.1016/s1474-4422(10)70196-4. PMID: 20801085.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-1618-7386 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_03833082cb2214312547c4d5645c0cb8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f0d5c90e66b486a5476c3841d173c596 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5426d8708e0b04f59eaba881ab98abf2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1d38ef19f2e1848aa1c342438da15b44 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_68e84fddcf0077bde138d29ac3b0028a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_188a5e9db9d16466b239eefec7669dcb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d34de24cd312c3a24c5ff7abfac4d225 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c7cefb1099ead0c346d021c9422fcd62 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a0df86f942e1a41f6f9a24450d2aa866 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_671f6e9a5236676698059a8df8750a09 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_828dc8ef4e40ce96ef13e5076c1c54c7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f1b3dac36b772b39882c49f4bea5cc41 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1d99e4e7e72cd98c93d96566fdaee4ac http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_db53617d1b51a85668c3a2e24706e7a7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e25b8c518bbd8ce2c9f1b2bc10a722b0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8b9be6b55f397c38ed5f0ce93e70534c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dae41797cd820c2da9cd44bd9384b605 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7325b12d12340625849afc5a9e621ae7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a59a921b085e4a8df46d447353660fcd
date	201011
identifier	https://doi.org/10.1016/s1474-4422%2810%2970196-4 https://pubmed.ncbi.nlm.nih.gov/20801085
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/30413 https://portal.issn.org/resource/ISSN/1474-4422
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial
discusses	http://id.nlm.nih.gov/mesh/M0025279
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D020388Q000188 http://id.nlm.nih.gov/mesh/D016572Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D012196 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D002648 http://id.nlm.nih.gov/mesh/D020388Q000503 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008297
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5865 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8545 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284373 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7922 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10573 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9079 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10325

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135979775 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129717275

Total number of triples: 58.